Eye-sparing treatment options for children with retinoblastoma
Part of Cancer, Eyes & vision clinical trials.
This trial studies whether newer “save-the-eye” treatment plans can control retinoblastoma (eye cancer) while keeping vision as good as possible. It compares different conservative treatment strategies depending on how the tumor looks and where it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be newly diagnosed with retinoblastoma (not a past recurrence).
- At least one eye must be eligible for conservative (eye-sparing) treatment based on tumor features seen by the study team.
- Your child must be between 6 months and 6 years old for the main study option, and under 6 months for some conservative options.
- Your child must not have received chemotherapy or radiation for any cancer before this study (including for retinoblastoma).
- A parent/legal guardian must give consent, and you must be able to attend frequent visits and follow-up.
- The study team must find no reason your child cannot receive the planned treatments (for example, a medical allergy/contraindication to study medicines).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at care recommendations for children with retinoblastoma (a childhood eye cancer). It may help standardize the best treatment approach for different patterns of tumor spread.
This trial tests a high dose of a chemotherapy drug called topotecan given directly into the eye (intravitreal injection) for children with retinoblastoma that has come back or not responded to treatment and has seeds floating in the vitreous. The goal is to save the eye when removal is the only other option.
This trial studies whether a combination chemotherapy treatment (topotecan plus melphalan) can help children with retinoblastoma while keeping the eye when possible. It’s a Phase 3 study, meaning it’s testing effectiveness in a larger group of patients.
This trial tests a new way to deliver the chemotherapy drug topotecan directly to the eye (via a small patch placed on the eye surface) for children with retinoblastoma that either needs eye removal or has come back after standard treatment. It aims to see if this approach can help save the eye and vision.
This Phase 3 study tests whether giving chemotherapy after the eye has been removed can lower the chance of retinoblastoma coming back for children with high-risk disease. You may be screened if your child had one eye affected and meet the staging and treatment history requirements.
This trial tests an experimental drug that targets a specific gene (NUDT21) to treat retinoblastoma that has not responded to standard treatments. It is for children who have active tumor in only one eye and whose only other option is to remove the eye, but who want to try to save the eye instead.
Hear when a new Retinoblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.